MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS)

Last updated: August 6, 2024
Sponsor: Aristotle University Of Thessaloniki
Overall Status: Active - Recruiting

Phase

N/A

Condition

Atherosclerosis

Thrombosis

Chest Pain

Treatment

Minimal Invasive Extracorporeal Circulation

Conventional cardiopulmonary bypass

Clinical Study ID

NCT05487612
MiECS
  • Ages 18-85
  • All Genders

Study Summary

MiECS is one of the largest multicentre randomised controlled trials on extracorporeal circulation conducted under the auspices of Minimal Invasive Extracorporeal Technologies International Society (MiECTiS). It is designed to ultimately address the emerging effectiveness of MiECC systems in the light of modern perfusion practice worldwide. The primary hypothesis is that MiECC, as compared to conventional CPB (cCPB), reduces the proportion of patients experiencing serious perfusion-related postoperative morbidity after cardiac surgery. The study will be led by the Clinical Research Unit of the Special Unit for Biomedical Research and Education (SUBRE), Aristotle University of Thessaloniki School of Medicine in Greece (AUSoM) with Chief Investigator Professor Kyriakos Anastasiadis, who is a key-opinion-leader in the field of MiECC, founder and Executive Board of MiECTiS.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • All patients undergoing any elective or urgent coronary artery bypass grafting (CABG), aortic valve replacement (AVR) or CABG+AVR surgery using extracorporealcirculation without circulatory arrest.

Exclusion

Exclusion Criteria:

  • Requirement for emergency or salvage operation.

  • Requirement for major aortic surgery (e.g. aortic root replacement).

  • Contraindication or objection (e.g. Jehovah's Witnesses) to transfusion of bloodproducts.

  • Congenital or acquired platelet, red cell or clotting disorders (patients with irondeficient anaemia will not be excluded).

  • Inability to give informed consent for the study (e.g. learning or languagedifficulties).

Study Design

Total Participants: 1300
Treatment Group(s): 2
Primary Treatment: Minimal Invasive Extracorporeal Circulation
Phase:
Study Start date:
May 26, 2022
Estimated Completion Date:
March 31, 2027

Study Description

Despite a fall in mortality rates over the past decade, patients having cardiac surgery continue to experience serious postoperative complications. The risk of serious and relatively common surgical complications is often a consequence of stopping the heart during the operation, using the heart and lung machine (conventional cardiopulmonary bypass; cCPB), and restarting and reperfusing the heart at the end of the operation. Although several strategies have been developed to reduce such complications, they still occur and can be life threatening; they also increase the length of time a patient spends in the hospital.

Miniaturised heart lung machines (minimally invasive extracorporeal circulation; MiECC) have been developed with the aim of reducing the number of postoperative complications arising from using cCPB. Because of the variety of miniaturised systems that have been evaluated, the different types of patients and outcomes investigated, and the poor quality of previous studies, the effectiveness of MiECC in reducing postoperative complications has not been established and most hospitals continue to use cCPB.

Our primary hypothesis is that, compared to cCPB, using a MiECC system during cardiac surgery reduces the proportion of patients having one of several serious postoperative complications (death, myocardial infarction, stroke, acute kidney injury, reintubation, tracheostomy, mechanical ventilation for more than 48 hours, or reoperation) up to 30 days after surgery. In addition, the investigators hypothesise that MiECC reduces the amount of blood products transfused, time to discharge from the cardiac intensive care unit and hospital and the health care resources used during the hospital stay.

Study investigators propose to carry out a large, multicentre randomised controlled trial in 10 to 15 cardiac surgery centres worldwide. Patients will be eligible if they are having coronary artery bypass surgery, aortic valve replace or both using a heart lung machine without circulatory arrest. Centres may recruit patients having all, or a subset of, operation types.

It is expected that 20 % to 23% of patients will experience one or more of the serious complications (the primary outcome). In order to be able confidently to detect a 30% relative reduction in the risk of this outcome, the investigators plan to recruit 1,300 participants across all sites.

Connect with a study center

  • Perfusion Services University Health Network, Toronto General Hospital

    Toronto, M5G 2C4
    Canada

    Active - Recruiting

  • Department of Cardiothoracic and Vascular Surgery

    Braunschweig, 38126
    Germany

    Site Not Available

  • Department of Cardiac Surgery

    Coswig, 06869
    Germany

    Site Not Available

  • Department of Thoracic and Cardiovascular Surgery, University Medical Centre Goettingen

    Göttingen,
    Germany

    Site Not Available

  • Department of Cardiothoracic and Vascular Surgery, Ulm University Hospital

    Ulm, 89081
    Germany

    Completed

  • Cardiothoracic Department AHEPA University Hospital

    Thessaloníki, 54636
    Greece

    Active - Recruiting

  • Department of Cardiac Surgery GVM Anthea Hospital

    Bari, 70124
    Italy

    Active - Recruiting

  • Department of Cardiac Surgery GVM Maria Eleonora Hospital

    Palermo, 90135
    Italy

    Site Not Available

  • Department of Cardiovascular Surgery, University Hospital Bern

    Bern, CH-3010
    Switzerland

    Site Not Available

  • Department of Cardiovascular Surgery, Ankara City Hospital

    Ankara,
    Turkey

    Site Not Available

  • Department of Cardiovascular Surgery, Izmir Bakırçay University, Faculty of Medicine

    Izmir,
    Turkey

    Active - Recruiting

  • Department of Cardiac Surgery, Royal Papworth Hospital

    Cambridge, CB2 0AY
    United Kingdom

    Site Not Available

  • Deparment of Cardiac Surgery, Castle Hill Hospital

    Hull, HU16 5JQ
    United Kingdom

    Site Not Available

  • Department of Cardiothoracic Surgery, Hammersmith Hospital

    London, W120HS
    United Kingdom

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.